News
OCGN
1.500
+0.67%
0.010
Weekly Report: what happened at OCGN last week (0629-0703)?
Weekly Report · 1d ago
Largest borrow rate increases among liquid names
TipRanks · 5d ago
Ocugen to present modifier gene therapy platform at Piper Sandler Virtual Ophthalmology Day
PUBT · 6d ago
Ocugen Inc. Stock Climbs 11.3%, Outperforms Market
Dow Jones · 06/29 20:32
Weekly Report: what happened at OCGN last week (0622-0626)?
Weekly Report · 06/29 09:34
Ocugen Inc. Stock Climbs 9.5%, Outperforms Market
Dow Jones · 06/26 20:32
Ocugen: Financing Risk Is Lower, But The Clinical Bet Still Has To Work
Seeking Alpha · 06/25 04:35
Ocugen Inc. Stock Climbs 7.0%, Outperforms Market
Dow Jones · 06/23 20:35
Weekly Report: what happened at OCGN last week (0615-0619)?
Weekly Report · 06/22 09:38
Nasdaq, Take-Two, Fastly, Ocugen, Sony Insider Shock
TipRanks · 06/20 13:01
Top Ocugen Executive Makes Bold Insider Move
TipRanks · 06/18 02:08
Ocugen CFO Treerita Johnson-Greene acquires 21,000 common shares for $25,830
PUBT · 06/17 20:14
Weekly Report: what happened at OCGN last week (0608-0612)?
Weekly Report · 06/15 09:39
Ocugen Stockholders Approve Proposals and Confirm Leadership
TipRanks · 06/11 22:56
Ocugen shareholders elected Castillo, Chandran to board in annual meeting vote
PUBT · 06/11 21:20
Weekly Report: what happened at OCGN last week (0601-0605)?
Weekly Report · 06/08 09:37
Ocugen Consolidates Financial Leadership Under New Accounting Officer
TipRanks · 06/03 22:09
Ocugen CFO Rita Johnson-Greene takes over as principal accounting officer after CAO resignation
PUBT · 06/03 20:36
Ocugen's Gene-Agnostic Eye Therapies Could Reshape Late-Stage Care
NASDAQ · 06/03 15:50
Is OCGN Stock Worth the Risk Ahead of 2026-27 Eye Gene Therapy Data?
NASDAQ · 06/03 15:39
More
Webull provides a variety of real-time OCGN stock news. You can receive the latest news about Ocugen Inc through multiple platforms. This information may help you make smarter investment decisions.
About OCGN
Ocugen, Inc. is a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines that improve health and offer hope for patients across the globe. Its technology pipeline includes Novel Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, and Inhaled Mucosal Vaccine Platform. It is developing its modifier gene therapy platform, inclusive of OCU400, OCU410, and OCU410ST, for the treatment of multiple inherited retinal diseases, including retinitis pigmentosa, Stargardt disease and multifactorial diseases, such as dry age-related macular degeneration (dAMD) and geographic atrophy. It is developing a next-generation, inhalation-based mucosal vaccine platform based on a novel ChAd vector, which includes OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine, and OCU520, a combination quadrivalent seasonal flu.